Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$0.00$0.00derived— vs Q3 2018 Net Income-$21.57M-$21.57MN/M vs Q3 2018 EPS Diluted-$0.66-$0.66N/M vs Q3 2018 Operating Income-$22,146,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Operating Cash Flowderived-$17,208,000N/M Free Cash Flowderived-$17,351,000N/M ended Sep 30, 2019 · filed Nov 6, 2019 · 37 d after period end